XML 23 R11.htm IDEA: XBRL DOCUMENT

Special Charges and Certain Litigation Charges	9 Months Ended
Special Charges and Certain Litigation Charges	Jan. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Special Charges and Certain Litigation Charges	Special Charges and Certain Litigation Charges Special Charges During the three and nine months ended January 29, 2016, there were no special charges. During the three months ended January 23, 2015, the Company recognized a $138 million gain, which consisted of a $41 million gain on the sale of a product line in the Surgical Technologies division, and a $97 million gain on the sale of an equity method investment. In addition, during the nine months ended January 23, 2015, continuing the Company's commitment to improving the health of people and communities throughout the world, the Company made a $100 million charitable cash contribution to meet the multi-year funding needs of the Medtronic Foundation, a related party non-profit organization. Certain Litigation Charges The Company classifies material litigation reserves and gains recognized as certain litigation charges. During the three months ended January 29, 2016, there were no certain litigation charges. During the nine months ended January 29, 2016, the Company recorded certain litigation charges of $26 million, which relates to probable and reasonably estimable INFUSE product liability litigation. During the three and nine months ended January 23, 2015, there were no certain litigation charges.